Blueprint Medicines Co. Expected to Earn Q3 2022 Earnings of ($2.27) Per Share (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) – Research analysts at Oppenheimer raised their Q3 2022 earnings estimates for Blueprint Medicines in a research note issued to investors on Tuesday, August 2nd. Oppenheimer analyst M. Biegler now forecasts that the biotechnology company will post earnings per share of ($2.27) for the quarter, up from their prior forecast of ($2.31). Oppenheimer has a “Outperform” rating and a $80.00 price objective on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($7.70) per share. Oppenheimer also issued estimates for Blueprint Medicines’ Q4 2022 earnings at ($2.25) EPS, FY2022 earnings at ($9.00) EPS, Q1 2023 earnings at ($2.11) EPS, Q2 2023 earnings at ($1.89) EPS, Q3 2023 earnings at ($1.96) EPS, Q4 2023 earnings at ($1.72) EPS, FY2023 earnings at ($7.68) EPS, FY2024 earnings at ($4.32) EPS and FY2025 earnings at ($3.46) EPS.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last released its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported ($2.68) EPS for the quarter, missing analysts’ consensus estimates of ($2.23) by ($0.45). The firm had revenue of $36.55 million during the quarter, compared to the consensus estimate of $37.61 million. Blueprint Medicines had a negative net margin of 304.41% and a negative return on equity of 45.89%. Blueprint Medicines’s revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.86) earnings per share.

BPMC has been the topic of several other reports. Stifel Nicolaus decreased their price target on shares of Blueprint Medicines from $98.00 to $90.00 in a research note on Friday, July 1st. The Goldman Sachs Group lifted their price target on shares of Blueprint Medicines from $126.00 to $143.00 and gave the company a “buy” rating in a report on Wednesday. Raymond James cut their price target on shares of Blueprint Medicines from $133.00 to $115.00 and set a “strong-buy” rating on the stock in a report on Wednesday. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Monday, May 9th. Finally, SVB Leerink boosted their target price on shares of Blueprint Medicines from $56.00 to $65.00 and gave the company a “market perform” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $91.47.

Blueprint Medicines Price Performance

Shares of BPMC opened at $68.14 on Friday. The company has a market capitalization of $4.06 billion, a P/E ratio of -5.74 and a beta of 0.94. Blueprint Medicines has a 1-year low of $43.46 and a 1-year high of $117.86. The firm’s 50 day simple moving average is $54.16 and its 200 day simple moving average is $61.29.

Institutional Trading of Blueprint Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC purchased a new stake in Blueprint Medicines during the 4th quarter valued at $34,000. Nisa Investment Advisors LLC raised its holdings in Blueprint Medicines by 50.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 684 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 230 shares during the period. Exane Derivatives raised its holdings in Blueprint Medicines by 45.8% during the 1st quarter. Exane Derivatives now owns 567 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 178 shares during the period. Steward Partners Investment Advisory LLC raised its holdings in Blueprint Medicines by 414.2% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 617 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 497 shares during the period. Finally, Prospera Financial Services Inc purchased a new stake in Blueprint Medicines during the 1st quarter valued at $42,000. Hedge funds and other institutional investors own 99.69% of the company’s stock.

Insider Activity

In related news, insider Percy H. Carter sold 1,908 shares of the stock in a transaction on Monday, June 6th. The stock was sold at an average price of $59.76, for a total transaction of $114,022.08. Following the sale, the insider now owns 28,685 shares in the company, valued at approximately $1,714,215.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.34% of the company’s stock.

Blueprint Medicines Company Profile

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

See Also

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Want More Great Investing Ideas?

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.